1. People's Republic of China Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Entest Group, Inc.

Entest Group, Inc.

ETNI
Entest Group, Inc.US flagOther OTC
0.00
USD
- -
- -
9,834.00Market Cap
Entest Group, Inc.
ETNI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
TTM
FRC
- -
- -
2.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-16.4
-4.66
-7.18
-3.03
-0.43
-0.14
-0.03
-0.01
-0.01
-0.03
- -
- -
Basic EPS, GAAP
-6.7
-1.89
-6.23
-1.46
-0.32
-0.14
- -
- -
-0.01
-0.03
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-15.29
-6.61
-12.98
-5.43
-1.45
-0.65
-0.4
-0.19
-0.2
-0.21
-0.2
-0.2
Book Value per Share
5.32
-1.89
-1.77
-0.86
-0.23
-0.07
-0.05
-0.02
-0.02
-0.03
-0.02
-0.02
Tangible Book Value per Share
- -
- -
- -
1
3
10
17
40
43
49
49
49
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-260.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-2
-1
-1
- -
-1
-1
-1
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-272.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-1
-1
-1
-1
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
-1
-1
-1
-1
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.1
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
May'19
Aug'19
Nov'20
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
49
49
49
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
May'19
Aug'19
Nov'20
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-130.98%
-341.73%
-86.7%
Free Cash Flow
143.14%
194.95%
-99.73%
Net Income, GAAP
27.25%
0.02%
-112.97%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
-0.01
-0.01
- -
-0.03
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
Similar Companies
SK Growth Opportunities Corporation (SKGRU)
Trajectory Alpha Acquisition Corp. (TCOA-UN)
Good Works II Acquisition Corp. (GWIIU)
All Things Mobile Analytic Inc. (ATMH)
Enphys Acquisition Corp. (NFYS-UN)
Constellation Acquisition Corp I (CSTA)
Business
Entest Group, Inc. (ETNI) operates as a shell company with no significant current operations and seeks merger, acquisition, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination opportunities with one or more operating businesses. The company, founded in 2008 and headquartered at No. 911 Bao’an Book City, Xinqiao Street Central Road, Shenzhen, Guangdong Province, China, previously focused on biotechnology product development including immunotherapeutic cancer vaccines for dogs under its former name Entest Biomedical, Inc., which it changed to Entest Group, Inc. in February 2018; it employs two staff members and trades on the OTC Markets with Peiwen Yu as president, chief executive officer, and director. It generates no revenue, reports minimal EBITDA of around $44,000 on a trailing twelve-month basis, and maintains a small market capitalization under $5 million with negligible trading volume. No recent partnerships, funding rounds, acquisitions, new product launches, or major strategic shifts have been announced in the last several years, reflecting its dormant status in the shell companies segment of the financials sector targeting unidentified operating entities globally.